<DOC>
	<DOCNO>NCT00685685</DOCNO>
	<brief_summary>The purpose study evaluate compare relative bioavailability therefore bioequivalence test formulation lovastatin tablet equivalent dose Mevacor® tablet single oral dose administer fasting condition .</brief_summary>
	<brief_title>Fasting Bioavailability Study Lovastatin Tablets Mevacor Tablets</brief_title>
	<detailed_description>The purpose study evaluate compare relative bioavailability therefore bioequivalence test formulation lovastatin tablet equivalent dose Mevacor® tablet single oral dose administer fasting condition . Fifty-four healthy , light/non/or ex-smoking , non-obese , male volunteer least 18 year age randomly assign crossover fashion receive two lovastatin dose regimen sequence 7 day washout period dose period . On morning Day 1 , overnight fast least 10 hour , subject receive either single oral dose test formulation , lovastatin ( 1 x 40 mg tablet ) , single oral dose reference formulation , Mevacor® ( 1 x 40 mg tablet ) . After 7 day washout period morning Day 8 , follow overnight fast least 10 hour , subject receive alternate regimen . Blood sample draw participant dose 24 hour post-dose confined basis time sufficient adequately define pharmacokinetics lovastatin . Blood sample continue non-confined basis 36 48 hour post-dose . A goal study evaluate safety tolerability regimen healthy volunteer . Subjects monitor throughout confinement portion study adverse reaction study drug and/or procedure . Vital sign monitor judged necessary physician charge . All adverse event whether elicited query , spontaneously report , observe clinic staff evaluate Investigator report subject 's case report form .</detailed_description>
	<mesh_term>Lovastatin</mesh_term>
	<mesh_term>L 647318</mesh_term>
	<mesh_term>Dihydromevinolin</mesh_term>
	<criteria>Availability volunteer entire study period willingness adhere protocol requirement evidence informed consent form ( ICF ) duly sign volunteer Male age least 18 body mass index ( BMI ) great equal 19 30 kg/m² Clinical laboratory value within laboratory 's state normal range ; within range , must without clinical significance Healthy accord laboratory result physical examination Light , non exsmokers . Light smoker define someone smoking 10 cigarette less per day , exsmokers define someone completely stop smoke least 3 month The informed consent form must sign volunteer , prior participation study Significant history hypersensitivity lovastatin related product well severe hypersensitivity reaction ( like angioedema ) drug Presence significant gastrointestinal , liver kidney disease , condition know interfere absorption , distribution , metabolism excretion drug know potentiate predispose undesired effect History significant gastrointestinal , liver kidney disease , surgery may affect drug bioavailability , include limited cholecystectomy Presence significant cardiovascular , pulmonary , hematologic , neurologic , psychiatric , endocrine , immunologic dermatologic disease Presence active liver disease unexplained persistent elevation serum transaminase Maintenance therapy drug , significant history drug dependency alcohol abuse ( &gt; 3 unit alcohol per day , intake excessive alcohol , acute chronic ) Any clinically significant illness previous 28 day day 1 study Use enzymemodifying drug previous 28 day day 1 study ( barbiturate , corticosteroid , phenylhydantoins , etc . ) Participation another clinical trial previous 28 day day 1 study Donation 500 mL blood ( Canadian Blood Services , HemaQuebec , clinical study , etc . ) previous 56 day day 1 study Positive urine screen drug abuse Positive result HIV , HBsAg antiHCV test</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>Therapeutic Equivalency</keyword>
</DOC>